Anavex life sciences announces new publication in medical journal: blarcamesine prevented cognitive impairment in animal model of alzheimer's disease

Pre-treatment with blarcamesine entirely prevented abeta-induced cognitive decline confirmed significant biomarker-response in hippocampus new york, aug. 20, 2025 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company focused on developing innovative treatments for alzheimer's disease, parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including rett syndrome, and other central nervous system (cns) disorders, today reported a peer-reviewed publication in the journal neuroscience letters, titled “prevention of memory impairment and hippocampal injury with blarcamesine in an alzheimer's disease model.”1 this study shows that a pre-treatment with blarcamesine prevented amyloid beta-induced memory impairment and brain oxidative injury suggesting that blarcamesine is an attractive candidate for alzheimer's disease pharmacological prevention.
AVXL Ratings Summary
AVXL Quant Ranking